

( (SINV (S-TPC-1 (NP-SBJ (NP A proposed conflict-of-interest policy)
			 (PP for
			     (NP (ADJP federally funded) biomedical researchers)))
		 (VP may
		     (VP thwart
			 (NP many high-technology new ventures))))
	,
	(VP say
	    (SBAR 0
		  (S *T*-1)))
	(NP-SBJ (NP financiers)
		,
		(NP researchers)
		and
		(NP university administrators))
	.))
( (S (NP-SBJ The
	     (NAC National Institutes
		  (PP of
		      (NP Health)))
	     policy)
     (VP would
         (VP require
             (S (NP-SBJ researchers)
                (VP to
                    (VP (VP cut
                            (NP (NP financial ties)
                                (PP with
                                    (NP health-care businesses))))
                        -- or
                        (VP lose
                            (NP their government money)))))))
     .))
( (S (PP Among
         (NP other concerns))
     ,
     (NP-SBJ the agency)
     (VP says
         (SBAR 0
               (S (NP-SBJ-1 (NP researchers)
			    (PP with
				(NP business ties)))
                  (VP are
                      (ADJP-PRD more likely
				(S (NP-SBJ-2 *-1)
				   (VP to
				       (VP falsify
					   (NP findings)
					   (SBAR-PRP in order
						     (S (NP-SBJ *-2)
							(VP to
							    (VP tout
								(NP new drugs)))))))))))))
     .))
( (S (SBAR-TMP As
	       (S (NP-SBJ (NP ties)
			  (PP between
			      (NP (NP academia)
				  and
				  (NP venture capital))))
		  (VP have
		      (VP blossomed
			  (PP-TMP in
				  (NP recent years))))))
     ,
     (NP-SBJ (NP governmental fear)
             (PP of
                 (NP abuse)))
     (VP has
         (VP risen))
     .))
((SINV (S-TPC-1 But
		(NP-SBJ the guidelines)
		(VP could
		    ``
		    (VP make
			(S (NP-SBJ (NP it)
				   (S *EXP*-2))
			   (ADJP-PRD impossible)
			   (S-2 (NP-SBJ *)
				(VP to
				    (VP commercialize
					(NP research))))))))
       , ''
       (VP says
	   (SBAR 0
		 (S *T*-1)))
       (NP-SBJ (NP Kenneth Smith)
	       ,
	       (NP (NP associate provost)
		   and
		   (NP (NP vice president)
		       (PP for
			   (NP research)))
		   (PP-LOC at
			   (NP (NP Massachusetts Institute)
			       (PP of
				   (NP Technology))))))
       .))
( (S (NP-SBJ The NIH)
     (VP is
         (VP asking
             (NP (NP grant recipients)
                 and
                 (NP others))
             (PP-CLR for
		     (NP (NP comments)
			 (PP on
			     (NP the proposed guidelines))))
             (PP-TMP until
		     (NP Dec. 15))))
     .))
( (S (PP-TMP After
	     (NP that))
     ,
     (NP-SBJ it)
     (VP will
         (VP make
             (NP (NP a final decision)
                 (PP on
                     (NP the policy)))))
     .))
((SINV (S-TPC-1 (NP-SBJ The guidelines)
		(VP could
		    (VP foil
			(NP (NP future arrangements)
			    (ADJP similar
				  (PP to
				      (NP (NP the deal)
					  (PP behind
					      (NP (NP Lithox Inc.)
						  ,
						  (NP a
						      (NAC-LOC Salem
							       ,
							       Mass.
							       ,)
						      start-up))))))))))
       ,
       (VP says
	   (SBAR 0
		 (S *T*-1)))
       (NP-SBJ (NP Robert Daly)
	       ,
	       (NP (NP a managing partner)
		   (PP of
		       (NP (NP TA Associates)
			   ,
			   (NP a venture-capital firm)))))
       .))
( (S (PP With
         (NP (QP $ 2.3 million) *U*))
     ,
     (NP-SBJ (NP he)
             and
             (NP other investors))
     (VP launched
         (NP-1 Lithox)
	 (NP-TMP last year)
	 (S-PRP (NP-SBJ *-1)
		(VP to
		    (VP market
			(NP (NP a gallstone cure)
			    (VP being
				(VP developed
				     (NP *)
				     (PP by
					 (NP-LGS (NP researchers)
						 (PP of
						     (NP (NP the University)
							 (PP of
							     (NP California))
							 (PP-LOC at
								 (NP San Diego)))))))))))))
     .))
( (S (NP-SBJ (NP The researchers)
             ,
             (SBAR (WHNP-2 who)
                   (S (NP-SBJ-1 *T*-2)
                      (VP are
                          (VP being
                              (VP financed
                                  (NP *-1)
                                  (PP by
                                      (NP-LGS the Lithox funds)))))))
             ,)
     (VP will
         (VP receive
             (NP a 
		 (NX (NX royalty)
		     , or
		     (NX (NX percentage)
			 (PP of
			     (NP sales)))
		     ,))
	     (SBAR-ADV if
		       (S (NP-SBJ their research)
			  (VP yields
			      (NP a commercial product))))))
     .))
( (S (S-TPC-1 But
	      (SBAR-PRP because
			(S (NP-SBJ (NP the University)
				   (PP of
				       (NP California)))
			   ,
			   (PP like
			       (NP many other universities))
			   ,
			   (VP shares
			       (NP its royalties)
			       (PP with
				   (NP researchers)))))
	      ,
	      (NP-SBJ it)
	      (VP may
		  (VP disqualify
		      (NP itself)
		      (PP-CLR from
			      (NP federal funds))
		      (PP-LOC under
			      (NP the proposed guidelines))))
	      ,)
     (NP-SBJ Mr. Daly)
     (VP says
	 (SBAR 0
	       (S *T*-1)))
     .))
( (S (NP-SBJ The high-tech industry)
     (VP is
         (ADJP-PRD full
		   (PP of
		       (NP (NP the kind)
			   (PP of
			       (NP arrangement))
			   (SBAR (WHNP-1 that)
				 (S (NP-SBJ the new guidelines)
				    (VP would
					(VP affect
					    (NP *T*-1)))))))))
     .))
( (S (PP For
         (NP instance))
     ,
     (NP-SBJ-2 (NP Commonwealth BioVentures Inc.)
	       ,
	       (NP a venture-capital concern)
	       ,)
     (NP-TMP last month)
     (VP invested
         (NP $ 600,000 *U*)
	 (S-PRP-CLR (NP-SBJ *-2)
		    (VP to
			(VP launch
			    (NP (NP Amira Inc.)
				,
				(NP (NP a
					(NAC-LOC Worcester
						 ,
						 Mass.
						 ,)
					concern)
				    (SBAR (WHNP-1 that)
					  (S (NP-SBJ *T*-1)
					     (VP will
						 (VP produce
						     (NP pharmaceuticals)))))))))))
     .))
( (S (NP-SBJ Scientists Rima Kaddurah-Daouk and Paul Schimmel) 
     (VP conducted
         (NP the initial research)
         (PP-LOC at
		 (NP (NP the Massachusetts Institute)
		     (PP of
			 (NP Technology)))))
     .))
( (S (SBAR-ADV While
	       (S (NP-SBJ-2 Ms. Kaddurah-Daouk)
		  (VP left
		      (NP MIT)
		      (S-PRP (NP-SBJ *-2)
			     (VP to
				 (VP head
				     (NP Amira)))))))
     ,
     (NP-SBJ-1 Prof. Schimmel)
     (VP will
         (VP continue
             (S (NP-SBJ *-1)
                (VP to
                    (VP (VP work
                            (PP-LOC at
				    (NP MIT)))
                        ,
                        (VP serve
                            (PP-CLR on
				    (NP (NP Amira 's)
					board)))
                        and
                        (VP own
                            (NP (NP a small equity stake)
				(PP in
				    (NP the company)))))))))
     .))
( (S (NP-SBJ The Amira transaction)
     (VP is
         (ADJP-PRD typical
		   (PP of
		       (NP (NP the way)
			   (SBAR (WHADVP-1 0)
				 (S (NP-SBJ venture-capital firms)
				    (VP are
					(VP approaching
					    (NP (NP the task)
						(PP of
						    (S-NOM (NP-SBJ *)
							   (VP commercializing
							       (NP biotechnology research)))))
					    (ADVP-MNR *T*-1)))))))))
     .))
( (SINV (S-TPC-1 (SBAR-ADV While
			   (S (NP-SBJ universities)
			      (VP develop
				  (NP the basic research))))
		 , ``
		 (NP-SBJ venture capitalists)
		 (VP are
		     (NP-PRD (NP the ones)
			     (VP (ADVP best)
				 positioned
				 (S (NP-SBJ *)
				    (VP to
					(VP finance
					    (NP its commercialization))))))))
	, ''
	(VP says
	    (S *T*-1))
	(NP-SBJ (NP Gloria W. Doubleday)
		(PP of
		    (NP Commonwealth)))
	.))
( (S ``
     (NP-SBJ This)
     (VP is
         (NP-PRD (NP the best way)
		 (SBAR (WHADVP-1 0)
		       (S (NP-SBJ *)
			  (VP to
			      (VP transfer
				  (NP technology)
				  (PP-CLR straight off 
					  (NP (NP the campuses)
					      (PP of
						  (NP universities))))
				  (ADVP-MNR *T*-1)))))))
     . ''))
( (S (S-TPC-2 But
	      (NP-SBJ the new guidelines)
	      (VP could
		  (VP prevent
		      (NP-3 (NP scientists)
			    (PP like
				(NP Prof. Schimmel)))
		      (PP-CLR from
			      (S-NOM (NP-SBJ-1 *-3)
				     (VP being
					 (VP involved
					     (NP *-1)
					     (PP-CLR with
						     (NP (NP start-ups)
							 (PP such
							     as
							     (NP Amira))))))))))
	      ,)
     (NP-SBJ venture capitalists)
     (VP point 
	 (PRT out)
	 (SBAR 0
	       (S *T*-2)))
     .))
( (S (S-TPC-2 And
	      (SBAR-ADV if
			(S (NP-SBJ that)
			   (VP happens)))
	      ,
	      (NP-SBJ-1 (NP the entire process)
			(PP of
			    (S-NOM (NP-SBJ *)
				   (VP transferring
				       (NP technology)
				       (PP-DIR to
					       (NP the marketplace))))))
	      (VP could
		  (VP be
		      (VP harmed
			  (NP *-1))))
	      ,)
     (NP-SBJ they)
     (VP say
	 (SBAR 0
	       (S *T*-2)))
     .))
( (S (NP-SBJ (NP The stakes)
             (PP-LOC in
		     (NP the controversy)))
     (VP are
         (ADJP-PRD large))
     .))
( (S (NP-TMP Last year)
     ,
     (NP-SBJ-1 venture capitalists)
     (VP spent
         (NP an (QP estimated $ 600 million) *U*)
	 (S-PRP-CLR (NP-SBJ *-1)
		    (VP to
			(VP finance
			    (NP start-up companies)
			    (PP-LOC in
				    (NP (UCP medical and biotechnology) businesses)))))
	 ,
	 (PP according
	     (PP to
		 (NP (NP the National Venture Capital Association)
		     ,
		     (NP a trade group)))))
     .))
( (S (NP-SBJ (NP Many)
             (PP of
                 (NP the deals)))
     (VP involved
         (NP (NP transactions)
             (SBAR (WHPP-1 in
			   (WHNP which))
                   (S (NP-SBJ-2 scientific institutions or researchers)
                      (VP agreed
                          (S (NP-SBJ *-2)
                             (VP to
                                 (VP commercialize
                                     (NP their work))))
                          (PP in
                              (NP (NP return)
                                  (PP for
				      (NP (NP an equity stake)
					  or
					  (NP royalties)))))
			  (PP-LOC *T*-1))))))
     .))
((SINV (S-TPC-1 (PP-LOC In
			(NP (NP many)
			    (PP of
				(NP these deals))))
		, ``
		(NP-SBJ venture capitalists)
		(VP had
		    (NP the inside track)))
       , ''
       (VP says
	   (SBAR 0
		 (S *T*-1)))
       (NP-SBJ (NP Lawrence Bock)
	       (PP of
		   (NP (NP Avalon Ventures)
		       ,
		       (NP-LOC (NP La Jolla)
			       ,
			       (NP Calif)))))
       .))
( (S (S-TPC-2 (NP-SBJ-1 Investors)
	      (VP were
		  (ADJP-PRD willing
			    (S (NP-SBJ *-1)
			       (VP to
				   (VP gamble
				       (PP-CLR on
					       (NP new technologies))
				       (SBAR-PRP because
						 ``
						 (S (NP-SBJ we)
						    (VP had
							(NP (NP exclusive rights)
							    (PP to
								(NP those technologies))))))))))))
     , ''
     (NP-SBJ he)
     (VP adds
	 (SBAR 0
	       (S *T*-2)))
     .))
( (S But
     (PP-LOC under
	     (NP the proposed guidelines))
     ,
     (NP-SBJ-2 all (ADJP federally funded) research)
     (VP will
         (VP have
             (S (NP-SBJ-1 *-2)
                (VP to
                    (VP be
                        (VP reported
                            (NP *-1)
                            (ADVP-MNR publicly)
                            (SBAR-PRP so that
				      (S (NP-SBJ anyone)
					 (VP can
					     (VP capitalize
						 (PP-CLR on
							 (NP the work))))))))))))
     .))
( (S ``
     (S-TPC-1 (PP Without
		  (NP the exclusivity))
	      ,
	      (NP-SBJ most venture capitalists)
	      (VP wo n't
		  (VP have
		      (NP the incentive
			  (S (NP-SBJ *)
			     (VP to
				 (VP invest
				     (PP-CLR in
					     (NP such deals)))))))))
     , ''
     (NP-SBJ Mr. Bock)
     (VP says
	 (S *T*-1))
     .))
( (S (NP-TMP Last year)
     ,
     (PP for
         (NP example))
     ,
     (NP-SBJ-1 Avalon
	       and
	       others)
     (VP invested
         (NP (QP $ 14 million) *U*)
         (PP-LOC-CLR in
		     (NP (NP Athena Neurosciences Inc.)
			 ,
			 (NP-LOC (NP South San Francisco)
				 ,
				 (NP Calif.))))
	 ,
	 (S-PRP (NP-SBJ *-1)
		(VP to
		    (VP license and develop
			(NP (NP technology)
			    (PP for
				(NP (NP delivery)
				    (PP of
					(NP drugs))
				    (PP to
					(NP the brain)))))))))
     .))
( (S (S-TPC-2 But
	      (SBAR-TMP before
			(S (NP-SBJ-1 Athena)
			   (VP was
			       (ADJP-PRD able
					 (S (NP-SBJ *-1)
					    (VP to
						(VP get
						    (NP (NP an exclusive license)
							(PP to
							    (NP the technology))))))))))
	      ,
	      (NP-SBJ the Federal Register)
	      (VP published
		  (NP (NP most)
		      (PP of
			  (NP the details)))
		  ,
		  ``
		  (S-ADV (NP-SBJ *)
			 (VP giving
			     (NP (NP all)
				 (PP of
				     (NP (NP the company 's)
					 potential competitors)))
			     (NP a chance
				 (S (NP-SBJ *)
				    (VP to
					(VP exploit
					    (NP it)))))))))
     , ''
     (NP-SBJ Mr. Bock)
     (VP says
	 (SBAR 0
	       (S *T*-2)))
     .))
( (S (NP-SBJ Athena)
     (VP (VP (ADVP-TMP eventually)
	     acquired
	     (NP (NP exclusive rights)
		 (PP to
		     (NP the technology))))
	 and
	 (VP (ADVP-TMP currently) 
	     is
	     (VP developing
		 (NP it))))
     .))
( (SINV But
	,
	(VP says
	    (S *ICH*-1))
	(NP-SBJ Mr. Bock)
	,
	``
	(S-1 (NP-SBJ It)
	     (VP was
		 (NP-PRD a close call)))
	.
	''))
( (S (S-TPC-1 (NP-SBJ The proposed guidelines)
	      (VP could
		  (ADVP also)
		  (VP (VP delay
			  (NP commercialization))
		      --
		      and
		      (VP force
			  (S (NP-SBJ small companies)
			     (VP to
				 (VP waste
				     (NP scarce capital))))))))
     ,
     (NP-SBJ entrepreneurs)
     (VP say
	 (SBAR 0
	       (S *T*-1)))
     .))
( (SINV (S-TPC-1 (SBAR-ADV If
			   (S (NP-SBJ start-ups)
			      (VP ca n't
				  (VP have
				      (NP (NP early access)
					  (PP to
					      (NP (NP research)
						  (VP being
						      (VP conducted
							  (NP *) 
							  (PP-LOC at
								  (NP institutions)))))))))))
		 , ``
		 (NP-SBJ-2 we)
		 (VP have
		     (S (NP-SBJ *-2)
			(VP to
			    (VP (VP replicate
				    (NP it)
				    (NP-ADV ourselves))
				or
				(VP do
				    (PP-CLR without
					    (NP the research))))))))
	, ''
	(VP says
	    (SBAR 0
		  (S *T*-1)))
	(NP-SBJ (NP Ruth Emyanitoff)
		,
		(NP (NP manager)
		    (PP of
			(NP business development))
		    (PP-LOC at
			    (NP (NP Applied bioTechnology Inc.)
				,
				(NP a
				    (NAC-LOC Cambridge
					     ,
					     Mass.
					     ,)
				    concern)))))
	.))
( (S (S-TPC-1 (S-NOM-SBJ (NP-SBJ *)
			 (VP Duplicating
			     (NP research)))
	      (VP is
		  (ADJP-PRD both
			    costly
			    and
			    time-consuming)
		  (PP for
		      (NP a start-up))))
     ,
     (NP-SBJ Ms. Emyanitoff)
     (VP says
	 (SBAR 0
	       (S *T*-1)))
     .))
( (S (PP For
         (NP its part))
     ,
     (NP-SBJ NIH)
     (VP insists
         (SBAR that
               (S (NP-SBJ its guidelines)
                  ``
                  (VP should not
                      (VP stifle
                          (NP (NP research creativity)
                              or
                              (NP (NP technology transfer)
                                  (PP from
				      (NP the research laboratory))
				  (PP to
				      (NP commercial use)))))))))
     . ''))
((SINV (S-TPC-4 (NP-SBJ-2 (NP Universities)
			  (PP such
			      as
			      (NP Harvard
				  and
				  MIT)))
		(VP should
		    (VP be
			(ADJP-PRD able
				  (S (NP-SBJ *-2)
				     (VP to
					 (VP develop
					     (NP (NP a way)
						 (SBAR (WHADVP-3 0)
						       (S (NP-SBJ *)
							  (VP to
							      (VP act
								  (PP-CLR as
									  (NP (NP brokers)
									      (PP for
										  (NP the individual scientists))))
								  (ADVP-MNR *T*-3)))))))))))))
       ,
       (VP says
	   (SBAR 0
		 (S *T*-4)))
       (NP-SBJ (NP Katherine Bick)
	       ,
	       (SBAR (WHNP-1 who)
		     (S (NP-SBJ *T*-1)
			(VP oversees
			    (NP the huge NIH grants program)
			    (PP-MNR as
				    (NP (NP its deputy director)
					(PP for
					    (NP extramural research))))))))
       .))
( (S (NP-SBJ NIH staff members)
     (VP believe
         (SBAR 0
               (S (NP-SBJ-2 the guidelines)
                  (VP are
                      (ADJP-PRD essential
				(S (NP-SBJ *-2)
				   (VP to
				       (VP prevent
					   (NP (NP the escalation)
					       (PP of
						   (NP (NP problems)
						       (SBAR (WHNP-1 that)
							     (S (NP-SBJ-3 *T*-1)
								(VP have
								    (ADVP already)
								    (VP begun
									(S (NP-SBJ *-3)
									   (VP to
									       (VP surface
										   (PP-LOC in
											   (NP scientific ventures))))))))))))))))))))
     .))
( (S (ADVP-TMP Not long ago)
     ,
     (NP-SBJ-1 (NP scientists)
               (VP holding
                   (NP (NP stock)
                       (PP-LOC in
			       (NP Spectra Pharmaceutical Services Inc.)))))
     (VP were
         (VP accused
             (NP-2 *-1)
             (PP-CLR of
		     (S-NOM (NP-SBJ-3 *-2)
			    (VP falsifying
				(NP research)
				(S-PRP (NP-SBJ *-3)
				       (VP to
					   (VP boost
					       (NP the stock)))))))))
     .))
( (S (NP-SBJ Many officials)
     (VP are
         (ADVP also)
         (ADJP-PRD concerned
		   (PP about
		       (NP (NP companies)
			   (VP getting
			       (NP (NP a `` free ride '')
				   (PP on
				       (NP government-sponsored research))))))))
     .))
( (S (NP-SBJ A congressional subcommitee)
     (VP has
         (VP been
             (VP investigating
                 (NP (NP the potential abuse)
		     (PP from
			 (NP (NP researchers)
			     (VP holding
				 (NP (NP stock)
				     (PP-LOC in
					     (NP (NP companies)
						 (VP exploiting
						     (NP their research))))))))))))
     .))
( (S (PP Among
         (NP other provisions))
     ,
     (NP-SBJ the NIH guidelines)
     (VP would
         (VP prohibit
             (NP-3 (NP researchers)
		   and
		   (NP (NP members)
		       (PP of
			   (NP their immediate families))))
             (PP-CLR from
		     (S-NOM (NP-SBJ *-3)
			    (VP holding
				(NP (NP stock)
				    (PP-LOC in
					    (NP (NP any company)
						(SBAR (WHNP-2 that)
						      (S (NP-SBJ-1 *T*-2)
							 (VP is
							     (VP affected
								 (NP *-1)
								 (PP by
								     (NP-LGS (NP the outcome)
									     (PP of
										 (NP their research))))))))))))))))
     .))
( (S (NP-SBJ (NP Ms. Bick)
             ,
             (NP the NIH administrator)
             ,)
     (VP says
         (SBAR 0
               (S (NP-SBJ the (UCP business and scientific) community)
                  (VP is
                      (VP overreacting
                          (PP-CLR to
				  (SBAR-NOM (WHNP-1 what)
					    (S (NP-SBJ the agency)
					       (ADVP merely)
					       (VP meant
						   (S (NP-SBJ *T*-1)
						      (VP to
							  (VP be
							      ``
							      (NP-PRD (NP ideas)
								      (PP for
									  (NP discussion)))))))))))))))
     . ''))
( (S (S-TPC-1 (NP-SBJ (NP The predictions)
		      (PP of
			  (NP doom)))
	      (VP are
		  ``
		  (ADJP-PRD premature)))
     , ''
     (NP-SBJ she)
     (VP says
	 (SBAR 0
	       (S *T*-1)))
     .))
( (S (S-TPC-2 But
	      (SBAR-TMP (WHADVP-1 when)
			(S (NP-SBJ (NP agencies)
				   (PP like
				       (NP the NIH)))
			   (VP circulate
			       (NP guidelines)
			       (ADVP-TMP *T*-1))))
	      ,
	      (NP-SBJ they)
	      (VP 've
		  (ADVP-TMP often)
		  (ADVP already)
		  (VP formulated
		      (NP policy))))
     ,
     (NP-SBJ veteran scientists)
     (VP say
	 (SBAR 0
	       (S *T*-2)))
     .))
( (S (ADVP Indeed)
     ,
     (NP-SBJ institutions)
     (ADVP already)
     (VP are
         (VP taking
             (NP-CLR note)))
     .))
( (S (PP-TMP On
	     (NP Sept. 14))
     ,
     (NP-SBJ-2 Harvard)
     (VP began
         (S (NP-SBJ *-2)
	    (VP circulating
		(NP (NP a conflict-of-interest policy statement)
		    (SBAR (WHNP-1 that)
			  ,
			  (S (PP in
				 (NP effect))
			     ,
			     (NP-SBJ *T*-1)
			     (VP would
				 (VP follow
				     (NP the NIH guidelines)
				     (ADVP-MNR faithfully)))))))))
     .))
( (S (NP-SBJ (NP The University)
             (PP of
                 (NP California))
	     (PP-LOC at
		     (NP San Francisco)))
     (VP is
         (ADVP also)
         (VP circulating
             (NP (NP a memo)
                 (SBAR *ICH*-1))
             (PP-CLR among
		     (NP its scientific faculty))
             (SBAR-1 (WHNP-2 that)
                     (S (NP-SBJ *T*-2)
                        (VP will
                            (VP restrict
                                (NP (NP contact)
                                    (PP with
                                        (NP (NP the world)
                                            (PP of
                                                (NP business)))))))))))
     .))
( (S (PP-LOC In
	     (NP many other institutions))
     ,
     (NP-SBJ scientists)
     (VP are
         (VP shunning
             (NP (NP contacts)
                 (PP with
                     (NP venture investors)))
             (SBAR-TMP until
		       (S (NP-SBJ-1 the NIH policy)
			  (VP is
			      (VP settled
				  (NP *-1)))))))
     .))
( (SINV (VP Says
	    (S *ICH*-1))
	(NP-SBJ (NP Mr. Daly)
		,
		(NP the venture capitalist))
	:
	``
	(S-1 (NP-SBJ (NP It)
		     (SBAR *EXP*-2))
	     (VP does n't
		 (VP matter
		     (SBAR-2 whether
			     (S (NP-SBJ they)
				(VP call
				    (S (NP-SBJ it)
				       (NP-PRD guidelines
					       or
					       policy))))))))
	.))
( (S (NP-SBJ-1 The damage)
     (VP is
         (ADVP already)
         (VP done
	     (NP *-1)))
     .))
